SCHEMBL74904

SCHEMBL74904

COc1ccc(C=CC(=O)N2CC(CCl)c3c2cc(N)c2ccccc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
GAA P10253 3/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
ADH1A P07327 1/20 0.44
KIT P10721 1/20 0.44
FLT1 P17948 1/20 0.44
FLT4 P35916 1/20 0.44
KDR P35968 1/20 0.44
ABL2 P42684 1/20 0.44
MAPT P10636 1/20 0.43
GPR183 P32249 3/20 0.42
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
HDAC1 Q13547 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KCNH2 Q12809 1/20 0.39
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26322204 1.00 ALDH1A1 (0.46) ALDH1A1GAALMNAHPGDADH1A
SCHEMBL74903 1.00 ALDH1A1 (0.46) ALDH1A1GAALMNAHPGDADH1A
SCHEMBL31237464 0.91 ADH1A (0.43) ALDH1A1ADH1AKITFLT1FLT4
SCHEMBL5623925 0.91 ADH1A (0.43) ALDH1A1ADH1AKITFLT1FLT4
SCHEMBL5623921 0.91 ADH1A (0.43) ALDH1A1ADH1AKITFLT1FLT4
SCHEMBL14499189 0.91 ALDH1A1 (0.47) ALDH1A1GAALMNAHPGDADH1A
SCHEMBL6206907 0.85 ADH1A (0.45) ALDH1A1LMNAADH1AKITFLT1
SCHEMBL6206911 0.85 ADH1A (0.45) ALDH1A1LMNAADH1AKITFLT1
SCHEMBL31238374 0.85 ADH1A (0.45) ALDH1A1LMNAADH1AKITFLT1
SCHEMBL21366179 0.85 ALDH1A1 (0.44) ALDH1A1GAALMNAHPGDADH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235578-B2 Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom AUCKLAND UNISERVICES LIMITED (NZ) 2007-06-26 US claimed
US-20050148651-A1 Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom AUCKLAND UNISERVICES LIMITED (NZ) 2005-07-07 US claimed
US-8129505-B2 Formed by catalytic polymerization; antibody conjugates UCB PHARMA S.A. (BE) 2012-03-06 US disclosed
EP-1926757-B1 ANTIBODY-COMB POLYMER CONJUGATE UCB PHARMA SA (BE) 2012-02-22 EP disclosed
US-20080220005-A1 Comb Polymers UCB PHARMA S.A. (BE) 2008-09-11 US disclosed
EP-1926757-A1 COMB POLYMERS UCB Pharma, S.A. (BE) 2008-06-04 EP disclosed
US-7235578-B2 Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom AUCKLAND UNISERVICES LIMITED (NZ) 2007-06-26 US disclosed
WO-2007031734-A1 COMB POLYMERS UCB PHARMA S.A. (BE) 2007-03-22 WO disclosed
EP-0938474-B1 CYCLOPROPYLINDOLE COMPOUNDS AND THEIR USE AS PRODRUGS AUCKLAND UNISERVICES LTD (NZ) 2005-11-23 EP disclosed
US-20050148651-A1 Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom AUCKLAND UNISERVICES LIMITED (NZ) 2005-07-07 US disclosed
WO-2003097635-A1 PROCESSES FOR PREPARING 3-SUBSTITUTED 1-(CHLOROMETHYL)-1,2-DIHYDRO-3H-[RING FUSED INDOL-5-YL(AMINE-DERIVED)] COMPOUNDS AND ANALOGUES THEREOF, AND TO PRODUCTS OBTAINED THEREFROM AUCKLAND UNISERVICES LIMITED (NZ) 2003-11-27 WO disclosed
US-6130237-A Condensed N-aclyindoles as antitumor agents CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2000-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148651-A1 Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom CBR3, ANPEP, CBR1 ALDH1A1 437/4885GAA 641/4885LMNA 4679/4885
US-20080220005-A1 Comb Polymers C9, F13B, PYM1 ALDH1A1 2973/4885GAA 3550/4885LMNA 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.